NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ElevateBio

ElevateBio

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://elevate.bio/

Last Round

Series D

May 24, 2023

Total Funding Raised

$1.25B

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ElevateBio is a biotechnology company that provides an integrated platform for the discovery, development, and manufacturing of cell and gene therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

cell and gene therapyCDMOgene editingbiomanufacturingcontract development and manufacturing organizationviral vector manufacturingprotein language modelsallogeneic cell therapyAI drug discoveryprocess developmentbiotech foundryCRISPRcGMP manufacturingLNP deliverybiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ElevateBio Comparables

Compare ElevateBio with similar companies based on industry and business-model similarity.

ElevateBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RoslinCT
85%
Resilience
83%
GeneFab
81%

ElevateBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DMay 24, 2023
Series CMar 15, 2021
Series BMar 30, 2020
Series AMay 13, 2019

Key People

Founding team and executive leadership

David Hallal

CEO, Chair, And Co-Founder

Founding Team

Michael Paglia

Chief Technology Officer, ElevateBio BaseCamp

Executive Team

Bhakti Bhargava

Chief Financial Officer

Executive Team

ElevateBio Investors

Notable investors and investment history

ElevateBio investors
InvestorRounds
EcoR1 CapitalSeries B, Series A, Series D, Series C
Redmile GroupSeries B, Series A, Series D, Series C
MPM CapitalSeries B, Series D, Series C, Series A
SoftBank Investment AdvisersSeries D, Series C
Fidelity Management & Research CompanySeries D, Series C
MPM BioImpactSeries A, Series B, Series D, Series C
SoftBank GroupSeries D, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 5, 2026

    Christopher Murphy named Chief Executive Officer and Board member.

  • Jan 5, 2026

    Chris appointed as the new Executive Chairman.

ElevateBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ElevateBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ElevateBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range495
Year Founded2017
Last FundingMay 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.